Peptide Receptor Radionuclide Therapy with Lu-177 Octreotate in patients with Somatostatin Receptor Expressing Neuroendocrine Tumors: Six Years Assessment

OBJECTIVES: Peptide receptor radionuclide therapy (PRRT) with radiolabeled somatostatin analogues is a promising treatment for patients with inoperable, well to moderately-differentiated metastatic neuroendocrine tumors (NETs). In continuation of our novel study with the radionuclide Lutetium 177 (L...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Clin Nucl Med
Main Authors: Delpassand, Ebrahim S., Hamiditabar, Mohammadali, Ali, Muzammil, Roys, Joseph, Wolin, Edward M., O’Dorisio, Thomas M., Ranganathan, David, Strosberg, Jonathan R.
Formato: Artigo
Idioma:Inglês
Publicado: 2017
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7733354/
https://ncbi.nlm.nih.gov/pubmed/28263217
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/RLU.0000000000001629
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares